N Masuda
11 Papers
80 Citations
N Masuda is an academic researcher. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation
Masaaki Kawahara,S Ushijima,T. Kamimori,Kodama N,M Ogawara,Kaoru Matsui,N Masuda,M Takada,T Sobue,Kiyoyuki Furuse +9 more
TL;DR: Patients with small-cell lung cancer who survive more than 2 years have a significantly increased risk of developing a second primary tumour and the cessation of cigarette smoking after successful therapy is associated with a significantly decreased risk of a secondPrimary tumour.
139
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
N Masuda,Masahiro Fukuoka,S. Kudoh,Yoko Kusunoki,Kaoru Matsui,Nobuhide Takifuji,Kazuhiko Nakagawa,M Tamanoi,T Nitta,T. Hirashima +9 more
TL;DR: A Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination, found that Hematologic toxicity was relatively mild.
104
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
N Masuda,Masahiro Fukuoka,A Fujita,Y Kurita,S Tsuchiya,Keiichi Nagao,S. Negoro,Hiroyoshi Nishikawa,Nobuyuki Katakami,Kazuhiko Nakagawa,Hisanobu Niitani +10 more
TL;DR: A combination of CPT-11 and cisplatin is very effective against non-small-cell lung cancer with acceptable toxicities.
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
Masahiro Fukuoka,N Masuda,S. Negoro,Kaoru Matsui,Takashi Yana,Shouji Kudoh,Yoko Kusunoki,M Takada,Masaaki Kawahara,M Ogawara,Kodama N,Kaoru Kubota,Kiyoyuki Furuse +12 more
TL;DR: RhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs and a significant improvement in survival.
56
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
Kaoru Matsui,N Masuda,Masahiro Fukuoka,Takashi Yana,T. Hirashima,Takefumi Komiya,Masashi Kobayashi,Masaaki Kawahara,S. Atagi,M Ogawara,S. Negoro,Shouji Kudoh,Kiyoyuki Furuse +12 more
TL;DR: A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC).
54